国产99热精品_欧美疯狂做受xxxx猛交_婷婷在线网站_日韩无遮挡毛片_欧美高清momspuss_欧美激情福利

美國Dyax
Dyax是一家生技制藥公司，專注在辨認抗體、小蛋白質和peptide化合物的藥物發現臨床發展，主要治療炎癥與癌癥，公司擁有噬菌體顯現法(Phage display)專利技術，是蛋白質表現及研究的重要技術之一。公司并開發和商業化DX - 88（ecallantide），用于治療16歲以上遺傳性血管水腫（栓塞）和其他血管性水腫的跡象。

 
Dyax’s mission is to discover, develop, and commercialize innovative biopharmaceuticals for unmet medical needs, while delivering outstanding value to patients and stockholders.

Strategy
Our therapeutic product candidates include fully human monoclonal antibodies as well as small proteins and peptides. Dyax is particularly focused on medical advances in the areas of oncology and inflammation. Our powerful discovery technology provides us the uncommon advantage of being able to both identify and then develop our own clinical leads. Our integrated approach also allows us to leverage this technology into revenue generating collaborations with other companies and researchers to further their own product pipelines.

History in Brief
The company was co-founded in 1995 by biotechnology entrepreneur Henry E. Blair, presently the Chairman, President and Chief Executive Officer of Dyax Corp. Dyax Corp. was formed by the merger between Biotage, a separations instrument chromatography firm, and Protein Engineering Corporation, from which we acquired our patented proprietary phage display technology. In 2003, Dyax sold its non-core business, Biotage, to focus exclusively on biotherapeutics.

Dyax Corp. issued an initial public offering (IPO) in August 2000 and is listed on the NASDAQ exchange (Ticker: DYAX). Our company is headquartered in Cambridge, Massachusetts.

Technology
Dyax’s core proprietary phage display technology allows for the rapid identification of compounds that bind with very high affinity and specificity to therapeutic targets. Utilizing phage display, we generate large diverse libraries of human antibodies, peptides, and proteins, which may be screened against disease-associated target molecules to identify potential binders. Automation allows us to rapidly screen these libraries for high-affinity binders. Our libraries’ vast size and diversity often yield multiple candidates, from which we can quickly select the single best therapeutic candidate.